检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
机构地区:[1]太原市中心医院,030009 [2]晋城市郊区医院
出 处:《山西医药杂志》2000年第4期296-298,共3页Shanxi Medical Journal
摘 要:目的 研究胸外伤患者可溶性白细胞介素 - 2受体 (s IL- 2 R)和肿瘤坏死因子 - α(TNF- α)在创伤感染发生机制中的作用。方法 根据胸外伤创伤严重程度评分 (AIS- ISS)分为 :≥ 16分组 36例 ,<16分组 30例 ,根据是否合并感染分为 :创伤组 46例 ,创伤感染组 2 0例。于入院后第 1、3、7、14天抽取血样 ,运用双抗体夹心 EL ISA法测定 :s IL - 2 R和 TNF-α含量。结果 1重症胸外伤组伤后第 1天 s IL - 2 R及 TNF-α水平皆高于胸外伤组和正常对照组 ;2创伤感染组 s IL - 2 R水平持续升高 ,3~ 7d最为显著 ,伤后 14d仍未降至正常水平 ,而创伤组无此改变。3创伤组和创伤感染组均见 TNF- α短暂升高。结论 重症胸外伤后 ,s IL- 2 R在细胞免疫功能紊乱及创伤感染的发生机制中起重要作用 ,而 TNF- α在创伤后早期病理过程中起重要作用。Objective To evaluate the role of solube interleukin-2 receptors (sIL-2R) and tumor necrosis factor-α (TNF-α) in the mechanism of traumatic infection.Methods Sixty-six chest injured patients were divided into an AIS-ISS≥16 group (n=36) and an AIS-ISS <16 group (n=30);according to whether infection occurred in hospital,they were further divided into two:a noninfection group (n=34) and an infection group (n=20);in addition,30 normal subjects as controls.The serum levels of sIL-2R and TNF-α were measured by enzyme linked immunosorbent assay (ELISA) technique on the 1st 3rd,7th and 14th posttraumatic days.Results Levels of sIL-2R and TNF-α increased significantly in patients with chest injury on the day of admission to AIS-ISS≥16 group,Compared with those in AIS-ISS <16 group and normal cotrols.A persistent elevation of sIL-2R was found in patients in infection group on days 1 through 14,with a peak value on the 3rd day to the 7th day,but no change in the noninfection group.A temporary elevation of TNF-α level was seen in both infection and non infection groups.Conclusion sIL-2R plays an important role in the mechanism of posttraumatic cellular immunological disturbances and infection in chest injured patients;TNF-α may be involved only in the early pathogenesis.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.1